142 related articles for article (PubMed ID: 12881196)
1. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates.
Hebert C; Norris K; Sauk JJ
J Drug Target; 2003 Feb; 11(2):101-7. PubMed ID: 12881196
[TBL] [Abstract][Full Text] [Related]
2. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
3. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
Sinkule JA; Rosen ST; Radosevich JA
Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
[TBL] [Abstract][Full Text] [Related]
5. The production of the endostatin precursor collagen XVIII in head and neck carcinomas is modulated by CBP2/Hsp47.
Ollins GJ; Nikitakis N; Norris K; Herbert C; Siavash H; Sauk JJ
Anticancer Res; 2002; 22(4):1977-82. PubMed ID: 12174873
[TBL] [Abstract][Full Text] [Related]
6. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells.
Froesch BA; Stahel RA; Zangemeister-Wittke U
Cancer Immunol Immunother; 1996 Jan; 42(1):55-63. PubMed ID: 8625367
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Xiang Q; Yang Y; Zhou Z; Zhou D; Jin Y; Zhang Z; Huang Y
Eur J Pharm Biopharm; 2012 Feb; 80(2):379-86. PubMed ID: 22101181
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen.
Stan AC; Radu DL; Casares S; Bona CA; Brumeanu TD
Cancer Res; 1999 Jan; 59(1):115-21. PubMed ID: 9892195
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates.
Shiah JG; Sun Y; Kopecková P; Peterson CM; Straight RC; Kopecek J
J Control Release; 2001 Jul; 74(1-3):249-53. PubMed ID: 11489502
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.
King HD; Yurgaitis D; Willner D; Firestone RA; Yang MB; Lasch SJ; Hellström KE; Trail PA
Bioconjug Chem; 1999; 10(2):279-88. PubMed ID: 10077478
[TBL] [Abstract][Full Text] [Related]
11. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
12. Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma.
Song JX; Li FQ; Cao WL; Jia X; Shi LN; Lu JF; Ma CF; Kong QQ
Target Oncol; 2014 Sep; 9(3):263-72. PubMed ID: 23943313
[TBL] [Abstract][Full Text] [Related]
13. Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.
Fowers KD; Kopeček J
Macromol Biosci; 2012 Apr; 12(4):502-14. PubMed ID: 22278817
[TBL] [Abstract][Full Text] [Related]
14. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
15. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker.
Greenfield RS; Kaneko T; Daues A; Edson MA; Fitzgerald KA; Olech LJ; Grattan JA; Spitalny GL; Braslawsky GR
Cancer Res; 1990 Oct; 50(20):6600-7. PubMed ID: 2208122
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages.
Dubowchik GM; Radia S; Mastalerz H; Walker MA; Firestone RA; Dalton King H; Hofstead SJ; Willner D; Lasch SJ; Trail PA
Bioorg Med Chem Lett; 2002 Jun; 12(11):1529-32. PubMed ID: 12031335
[TBL] [Abstract][Full Text] [Related]
18. Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro.
Vrouenraets MB; Visser GW; Stigter M; Oppelaar H; Snow GB; van Dongen GA
Int J Cancer; 2002 Apr; 98(5):793-8. PubMed ID: 11920653
[TBL] [Abstract][Full Text] [Related]
19. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
[TBL] [Abstract][Full Text] [Related]
20. A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth.
Zhao S; Zhao G; Xie H; Huang Y; Hou Y
Braz J Med Biol Res; 2012 Mar; 45(3):230-7. PubMed ID: 22267001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
